Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.12 USD
−215.79 M USD
0.00 USD
54.44 M
About Replimune Group, Inc.
Sector
Industry
CEO
Sushil Patel
Website
Headquarters
Woburn
Founded
2015
FIGI
BBG00L8Z22R1
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of REPL is 14.93 USD — it has increased by 35.11% in the past 24 hours. Watch Replimune Group, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Replimune Group, Inc. stocks are traded under the ticker REPL.
REPL stock has risen by 29.83% compared to the previous week, the month change is a 25.15% rise, over the last year Replimune Group, Inc. has showed a 41.79% increase.
We've gathered analysts' opinions on Replimune Group, Inc. future price: according to them, REPL price has a max estimate of 18.00 USD and a min estimate of 14.00 USD. Watch REPL chart and read a more detailed Replimune Group, Inc. stock forecast: see what analysts think of Replimune Group, Inc. and suggest that you do with its stocks.
REPL reached its all-time high on Nov 19, 2020 with the price of 54.85 USD, and its all-time low was 4.92 USD and was reached on May 29, 2024. View more price dynamics on REPL chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
REPL stock is 45.32% volatile and has beta coefficient of 1.80. Track Replimune Group, Inc. stock price on the chart and check out the list of the most volatile stocks — is Replimune Group, Inc. there?
Today Replimune Group, Inc. has the market capitalization of 1.02 B, it has increased by 2.31% over the last week.
Yes, you can track Replimune Group, Inc. financials in yearly and quarterly reports right on TradingView.
Replimune Group, Inc. is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
REPL earnings for the last quarter are −0.68 USD per share, whereas the estimation was −0.82 USD resulting in a 17.41% surprise. The estimated earnings for the next quarter are −0.76 USD per share. See more details about Replimune Group, Inc. earnings.
Replimune Group, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
REPL net income for the last quarter is −53.05 M USD, while the quarter before that showed −53.77 M USD of net income which accounts for 1.33% change. Track more Replimune Group, Inc. financial stats to get the full picture.
No, REPL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 331.00 employees. See our rating of the largest employees — is Replimune Group, Inc. on this list?
Like other stocks, REPL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Replimune Group, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Replimune Group, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Replimune Group, Inc. stock shows the buy signal. See more of Replimune Group, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.